TeamDrive
RUS
Leonid Melamed

Leonid Melamed

Founding Partner, Chairman of The Board of Directors

Телефоны:

+7 495 545-39-12

Send message

​Leonid has almost 30 years of management experience at large companies in various market sectors.

Leonid – one of the leader of the team, implementing a major pharmaceutical and medical project, the brainchild of its investors RUSNANO OJSC and the American firm Domain Associates LLC. RusnanoMedInvest LLC (RMI) was founded to implement this project. RMI is the largest venture capital company in life sciences in Eastern Europe, focusing on innovative pharmaceutical projects backed by sustainable, cutting edge technologies. Russian pharmaceutical company NovaMedica LLC is responsible for the localisation of the products and technologies in Russia. It was also founded to implement ambitious plans to create a new GMP-compliant production facility and facilitate the production of innovative drugs.

Leonid Melamed is the co-founder and Chairman of the Board of Directors of RMI Partners (venture capital investment company), which manages the healthcare projects, one of them - a venture capital fund RusnanoMedInvest (RMI). One of the main investment in the RMI portfolio is NovaMedica LLC. At the present time Leonid is a member of the Board of Directors of RusnanoMedInvest and from 2012 to 2017 he was a member of the Board of NovaMedica.

Leonid also is the co-founder and member of the Board of Directors of Doctor Ryadom (network of medical clinics), which among the first in Russia began to provide telemedicine services to its patients.

Earlier Leonid was the President and Chairman of the Management Board and member of the Board of Directors of Sistema JFSC (from 2008 to 2011). From 2006 to 2008, Leonid ran the telecommunications company Mobile TeleSystems (MTS OJSC) as President and Chairman of the Management Board. For 15 years from 1991 to 2006 Leonid participated in the creation and development of ROSNO insurance company. In 2003 he was the head of ROSNO as CEO and Chairman of the Management Board.

His personal “portfolio” includes Russneft OJSC as Chairman of the Board of Directors (2010-2012) and VTB OJSC as a member of the Supervisory Board (2012-2013).

Currently, Leonid is a member of the Government Expert Council of the Russian Federation, which was established to involve the business community in the preparation and implementation of the Government’s decisions.

Leonid graduated with honours from I.M. Sechenov Moscow Medical Academy and in 2006 became a Doctor of Medical Sciences.

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more